Docetaxel Chemotherapy In The Management Of Advanced And Metastatic Breast Cancer In Nigerians A Pilot Study
Main Article Content
Abstract
The aim of this study was to assess whether introduction of Docetaxel into the management will improve palliation of symptoms, quality of life, response rate and probably survival in breast cancer patients. A total of 19 patients referred from different medical centers in Nigeria were entered into the study. The age range was 25 to 52 years with a median of 34 years. The sex incidence was 18 females, 1 male. There were 7 patients in stage III and the duration of median response was 30 months. There were 12 patients in stage IV. Out of these 3 patients with brain metastasis had median response of 4 months. 4 patients with liver metastasis average duration of response was 22 months. 5 patients with pulmonary metastasis average duration of response was 20 months. In all,
16, out of the 19 patients (84%) had median response duration of 20 30 months. Better response rate could have been in patients with cerebral metastasis but for the fact that Docetaxel does not penetrate brain barrier. Multicentre studies are now needed to reconfirm the superiority of Doxetacel over existing cytotoxic chemotherapeutic drugs currently in use in the management of
advanced and metastatic breast cancer in Nigeria.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
How to Cite
References
1. Abioye AA. The Ibadan Cancer Registry 1960 1980. In “Cancer in Africa”. Proceedings of a workshop of the West African College of
Physicians held in Monrovia. Liberia 1981. Ed. D.A. Olatunbosun pp 1-32. Caxton Press (West Africa). Ibadan.
2. Campbell OB, Agwimah R, Oduola BI, Alawale E. Radiotherapy Management of breast cancer in 400 Nigerians. Nigerian Medical Journal 1998.
3. Ketiku KK. The pattern of Metastases in Nigerian Breast Cancer patients. Clinical Oncology 1986; 37: 563-565.
4. Denis JN, Greene AE, Gyenard D et. al. A highly efficient practical approach to natural taxol J. Am Chem. Soc. 1988; 110:5917-9.
5. Mangata lL, Adeline MT, Guenard D et al. Application of the Vicinal examination reaction with asym metricinduction to henusynthesis of laxel and analogies. Tetrahedron 1989; 45:177-90.
6. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of Solid tumours: A Systematic Review of Clinical Data. Lancet Oncol. 2005; (4) 229-39.
7. Bissery MC, Nohynek G, Sanderink GJ et al: Docetaxel (Taxotere): A Review of Preclinical and Clinical Experience. Part I: Preclinical Experience. Anticancer Drugs 1995; 6:339-68.
8. Bissery MC, Vrignaud P, Bayass M et al. In vitro evaluation of Taxotere (RP 56976, NSC 628503) in combination with cisplatin, doxorubicin or vincristine. Proc. Am Assoc Cancer Res. 1992; 33:443 Abstract.
9. Bissery MC, Vrignaud P, Bayass M et al. Taxotere synergistic combination with Cyclophosphamide, Etoposide and 5 Fluorouracil in mouse tumour models Proc Am Assoc. Cancer Res. 1993; 34:299. Abstract.
10. Park SH, Cho Ek, Bang SM, Shin DB, Lee YD. Docetaxel plus Cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a Phase II Clinical Trail. BUC Cancer: 2005; 22, 5(1): 21.